StreetInsider.com News Articles

CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline

Sun, 16 Aug 2026 07:00:00 -0400

HONG KONG, Aug 16, 2026 - (JCN Newswire) - - On August 16, 2026, CanSino Biologics Inc. ("CanSinoBIO"; HKEX: 06185/SHSE: 688185) announced that the New Drug Application (NDA) for its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed (for people aged six years and above; the "Td5cp Adolescent and Adult") has been formally accepted by China's National Medical Products Administration (NMPA). As a booster vaccine for adolescents and adults, the product was granted Priority Review status in May 2026. If approved and launched, it is expected to create synergies with the recently approved next-generation three-component DTaP

CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline

Sun, 16 Aug 2026 07:00:00 -0400

CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline

Sun, 16 Aug 2026 07:00:00 -0400

CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline

Sun, 16 Aug 2026 07:00:00 -0400

CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline

Sun, 16 Aug 2026 07:00:00 -0400

CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline

Sun, 16 Aug 2026 07:00:00 -0400

CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential

Tue, 24 Feb 2026 04:22:00 -0400

HONG KONG, Feb 24, 2026 - (JCN Newswire) - - CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the 'NMPA'), pursuant to which, the supplemental application to expand the age range of applicable population of the Company's Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the 'MCV4', trade name: Menhycia (R)') from 'children aged from 3 months to 3 years old (47 months)' to 'children aged from 3 months to 6 years old (83 months)' has been approved by NMPA.

This approval

CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential

Tue, 24 Feb 2026 04:22:00 -0400

This approval

CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential

Tue, 24 Feb 2026 04:22:00 -0400

This approval

CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential

Tue, 24 Feb 2026 04:22:00 -0400

This approval

Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle

Wed, 20 Aug 2025 07:30:00 -0400

HONG KONG, Aug 20, 2025 - (JCN Newswire) - - During 1H2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. As a leading enterprise in China's innovative vaccine sector, CanSino Biologics Inc.(688185.SH, 6185.HK; 'CanSinoBIO') once again delivered a solid performance.

According to its 2025 interim report, CanSinoBIO achieved revenue of RMB 382 million in the first half, up 26% from a year earlier, extending its growth streak. Although the company has yet to turn profitable, losses have narrowed significantly,

Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle

Wed, 20 Aug 2025 07:30:00 -0400

Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle

Wed, 20 Aug 2025 07:30:00 -0400

Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle

Wed, 20 Aug 2025 07:30:00 -0400

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health